Pulmonx Affirms FY2024 Sales Guidance to $81.00M-84.00M VS Est. 82.63M
Portfolio Pulse from Benzinga Newsdesk
Pulmonx (NASDAQ:LUNG) has reaffirmed its FY2024 sales guidance, projecting revenues between $81 million and $84 million, aligning closely with the market estimate of $82.63 million.
October 30, 2024 | 9:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pulmonx has reaffirmed its FY2024 sales guidance, projecting revenues between $81 million and $84 million, which aligns closely with the market estimate of $82.63 million.
The reaffirmation of sales guidance within the expected range suggests stability and predictability in Pulmonx's financial performance. This alignment with market estimates is likely to result in a neutral short-term impact on the stock price, as there are no surprises or deviations from expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100